GSK has announced a 50/50 joint venture with ... costs for the joint venture and subsequent development costs will be split equally. Both companies are committed to supporting the WHO’s global ...

GSK meanwhile has previously suggest that the HBV therapy could collectively achieve sales of more than £2 billion ($2.45 billion) at peak, part of a new wave of therapies that it reckons could ...

© 2025 American City Business Journals. All rights reserved. Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement ...